Actions in Support of Newborn Screening for Critical Congenital Heart Disease - United States, 2011-2018.


Journal

MMWR. Morbidity and mortality weekly report
ISSN: 1545-861X
Titre abrégé: MMWR Morb Mortal Wkly Rep
Pays: United States
ID NLM: 7802429

Informations de publication

Date de publication:
08 Feb 2019
Historique:
entrez: 8 2 2019
pubmed: 8 2 2019
medline: 9 2 2019
Statut: epublish

Résumé

In 2011, the U.S. Department of Health and Human Services added critical congenital heart disease (CCHD), which occurs in two of every 1,000 births, to the list of conditions recommended to states for universal newborn screening (1). Without early detection, infants with CCHD are at risk for substantial morbidity and death in the first weeks and months of life (2). Based on 2007-2013 data, deaths from CCHD and other cardiac causes in infants aged <6 months significantly declined in infants born in eight states after they had fully implemented mandated newborn CCHD screening policies by June 2013 (3). CDC collaborated with the American Academy of Pediatrics (AAP) and the Association of Public Health Laboratories' Newborn Screening Technical Assistance and Evaluation Program (NewSTEPs) to update a 2015 report (4) on states' actions toward adopting and implementing policies supporting CCHD newborn screening. In 2018, all 50 states and the District of Columbia (DC) had implemented CCHD screening policies, and, with one exception, all states mandated that screening be done (California mandates that screening be offered). However, not all states had data systems in place for tracking all screening results and outcomes. Ongoing evaluation activities, which rely on screening data, could help identify program improvement opportunities and monitor the impact of early identification of CCHD.

Identifiants

pubmed: 30730872
doi: 10.15585/mmwr.mm6805a3
pmc: PMC6366677
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107-111

Déclaration de conflit d'intérêts

All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Références

MMWR Morb Mortal Wkly Rep. 2012 Oct 26;61(42):849-53
pubmed: 23095953
Pediatrics. 2016 May;137(5):
pubmed: 27244826
MMWR Morb Mortal Wkly Rep. 2017 Aug 25;66(33):888-890
pubmed: 28837548
MMWR Morb Mortal Wkly Rep. 2015 Jun 19;64(23):625-30
pubmed: 26086632
Pediatrics. 2009 Aug;124(2):823-36
pubmed: 19581259
Int J Neonatal Screen. 2017 Dec 22;4(1):1
pubmed: 33072927
Birth Defects Res A Clin Mol Teratol. 2012 Dec;94(12):965-9
pubmed: 23184496
JAMA. 2017 Dec 5;318(21):2111-2118
pubmed: 29209720
Pediatrics. 2011 Nov;128(5):e1259-67
pubmed: 21987707

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH